1. AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1. (June 2017) Authors: Neelapu, S.S.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.J.; Miklos, D.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.; Siddiqi, T.; Lin, Y.; Timmerman, J.; Reagan, P.; Navale, L.; Jiang, Y.; Aycock, J.; Elias, M.; Wiezorek, J.; Go, W.Y. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CLINICAL IMPLICATIONS OF CYTOPENIAS BEYOND DAY 30 AFTER AXI‐CEL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Strati, P.; Adkins, S.; Nastoupil, L.; Westin, J.; Hagemeister, F.; Fowler, N.; Lee, H.J.; Fayad, L.; Samaniego, F.; Ahmed, S.; Varma, A.; Arafat, S.; Johncy, S.; Kebriaei, P.; Mulanovich, V.E.; Ariza Heredia, E.; Neelapu, S.S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. COMPREHENSIVE REPORT OF ANTI‐CD19 CHIMERIC ANTIGEN RECEPTOR T‐CELLS (CAR‐T) ASSOCIATED NON RELAPSE MORTALITY (CART‐NRM) FROM FAERS. (12th June 2019) Authors: Anand, K.; Pingali, S.; Ensor, J.; Neelapu, S.S.; Iyer, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN‐LABEL, PHASE II STUDY. (June 2017) Authors: Nastoupil, L.J.; Westin, J.; Fowler, N.; Fanale, M.; Samaniego, F.; Oki, Y.; Obi, C.; Cao, J.; Cheng, X.; Ma, M.; Wang, Z.; Chu, F.; Feng, L.; Zhou, S.; Davis, R.E.; Neelapu, S.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OUTCOMES OF PATIENTS ≥ 65 YEARS OF AGE IN ZUMA‐1, A PIVOTAL PHASE 1/2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN REFRACTORY LARGE B CELL LYMPHOMA. (12th June 2019) Authors: Neelapu, S.S.; Jacobson, C.A.; Oluwole, O.O.; Munoz, J.; Deol, A.; Miklos, D.B.; Bartlett, N.L.; Braunschweig, I.; Jiang, Y.; Kim, J.J.; Zheng, L.; Rossi, J.M.; Locke, F.L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 303 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI‐CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI‐CEL). (June 2017) Authors: Neelapu, S.S.; Rossi, J.M.; Locke, F.L.; Xue, A.; Better, M.; Zhang, X.; Ghobadi, A.; Lekakis, L.J.; Miklos, D.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.; Siddiqi, T.; Lin, Y.; Timmerman, J.; Reagan, P.M.; Navale, L.; Go, W.Y.; Wiezorek, J.; Bot, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PROGNOSTIC VALUE OF PRE‐TREATMENT PET SCAN IN PATIENTS WITH FOLLICULAR LYMPHOMA RECEIVING FRONTLINE THERAPY. (12th June 2019) Authors: Strati, P.; Ahmed, M.; Fowler, N.; Hagemeister, F.; Fayad, L.; Rodriguez, M.; Samaniego, F.; Wang, M.; Westin, J.R.; Romaguera, J.; Noorani, M.; Phansalkar, K.; Cheah, C.; Feng, L.; Davis, R.E.; Nastoupil, L.; Neelapu, S.S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SAFETY AND EFFICACY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN OLDER PATIENTS: RESULTS FROM THE US LYMPHOMA CAR‐T CONSORTIUM. (12th June 2019) Authors: Sano, D.; Lekakis, L.; Feng, L.; Nastoupil, L.J.; Jain, M.D.; Spiegel, J.Y.; Dahiya, S.; Lin, Y.; Ghobadi, A.; Lunning, M.; Hill, B.T.; Reagan, P.; Oluwole, O.; McGuirk, J.; Sehgal, A.; Deol, A.; Charalambos, A.; Goy, A.H.; Munoz, J.; Cashen, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. TREATMENT WITH COMBINATION OF LENALIDOMIDE AND RITUXIMAB ACHIEVES DURABLE RESPONSES IN A LONG TERM FOLLOW UP OF PATIENTS WITH INDOLENT NON‐HODGKIN'S LYMPHOMA. (June 2017) Authors: Chaudhry, M.; Nastoupil, L.; Samaniego, F.; Neelapu, S.S.; Hagemeister, F.B.; Fanale, M.A.; Fayad, L.; Westin, J.R.; Oki, Y.; Feng, L.; Fowler, N. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗